AADC gene therapy administered via a posterior approach: 18-month results from the PD-1102 trial in advanced Parkinson’s disease
Objective: To report 18-month safety and clinical outcomes from a phase 1, open-label trial of VY-AADC01 (NBIb-1817) for Parkinson’s disease (PD) patients with motor fluctuations.…Blood hexokinase reduction in de novo Parkinson’s disease and remodeling of glycolytic energy homeostasis with L-DOPA/Istradefylline combination therapy
Objective: To evaluate the glycolytic energy homeostasis in Parkinson’s disease (PD), and to define the effects of PD pharmacotherapies on glycolytic dynamics Background: Neuronal energy…Home validation of a smartphone-based tapping task to assess medication responsiveness in Parkinson’s disease
Objective: To validate a timed tapping task (TTT) on a smartphone to ascertain differences in OFF- and ON-phases in Parkinson’s disease (PD) in the home…Real-World Healthcare Resource Utilization in Patients with Parkinson’s Disease and Motor Fluctuations
Objective: To evaluate healthcare resource utilization (HCRU) patterns in patients with Parkinson’s disease (PD) and motor fluctuations (MF) with carbidopa/levodopa (CD/LD) and other adjunctive PD…The Levodopa in Early Parkinson’s disease (LEAP) study: Post-hoc analyses
Objective: We present the results of several post hoc analyses of the LEAP-study. Background: Among patients with Parkinson’s disease who were evaluated in the LEAP-study…Correlation Between Dyskinesia and Quality of Life at Baseline and After 12 months of Treatment with LCIG in Patients with Advanced Parkinson’s Disease
Objective: Evaluate the correlation between dyskinesia and quality of life (QoL) at baseline and after 12 months of treatment with levodopa-carbidopa intestinal gel (LCIG) in…Concerns in patients with Parkinson’s disease in China: A content analysis of data from social listening
Objective: To understand Parkinson’s disease (PD) patients’ unmet needs and optimize the communication strategy with them, we used social media listening (SML) to focus on…Utility of multigene panel testing for diagnosing parkinsonism and dystonia in a large cohort of >500 patients
Objective: Evaluate the utility of multigene Next-Generation Sequencing (NGS) for molecular diagnosis of parkinsonism and dystonia. Background: Parkinson's disease (PD) and dystonia are common neurodegenerative…Pridopidine for the treatment of Levodopa-induced Dyskinesia in patients with Parkinson’s disease
Objective: To assess the efficacy and safety of pridopidine in PD patients with Levodopa-induced dyskinesia (LID). Background: Pridopidine is a small molecule in clinical development…Levodopa Dose Equivalency for Opicapone and Safinamide
Objective: To provide a levodopa dose equivalency (LED) for opicapone and safinamide. Background: Tomlinson at al., provided a schedule to calculate LED of the different…
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 57
- Next Page »